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Introduction {#ijc31895-sec-0001}
============

The prospective identification and rational therapeutic targeting of tumor genomic alterations have revolutionized the care of patients with lung cancer. However, lung cancer remains one of the leading causes of cancer‐related deaths worldwide. Oncogenic mutations of the epidermal growth factor receptor (*EGFR*) tyrosine kinase domain are identified in a substantial subset of nonsmall cell lung cancers (NSCLCs), and patients with *EGFR*‐mutant lung cancers generally achieve better progression‐free survivals (PFS) when treated with EGFR tyrosine kinase inhibitors (TKIs), compared to standard chemotherapies.[1](#ijc31895-bib-0001){ref-type="ref"}, [2](#ijc31895-bib-0002){ref-type="ref"}, [3](#ijc31895-bib-0003){ref-type="ref"} Such mutations, which most commonly occur as either small in‐frame deletions in exon 19 (Ex19del) or point mutations in exon 21 (L858R), confer constitutive activity of the EGFR tyrosine kinase and sensitivity to EGFR TKIs.[4](#ijc31895-bib-0004){ref-type="ref"} Uncommon *EGFR* alterations, including rare point mutations and gene rearrangements, such as kinase domain duplications (KDDs) and gene fusions, have also been identified in previous studies.[5](#ijc31895-bib-0005){ref-type="ref"}, [6](#ijc31895-bib-0006){ref-type="ref"}, [7](#ijc31895-bib-0007){ref-type="ref"}

EGFR‐KDDs typically result from in‐frame tandem duplication of *EGFR* exons 18--25 and constitutively activate EGFR signaling by forming an intramolecule dimer. Such a recurrent alteration is often observed in lung, brain, and soft tissue cancers.[6](#ijc31895-bib-0006){ref-type="ref"} A few reports showed that patients with lung adenocarcinomas harboring the EGFR‐KDD alteration had significant antitumor responses to EGFR TKI therapies, including gefitinib, erlotinib, and afatinib.[5](#ijc31895-bib-0005){ref-type="ref"}, [6](#ijc31895-bib-0006){ref-type="ref"} Thus, those findings suggested that EGFR‐KDD represents a driver aberration and a therapeutically actionable target in NSCLC patients. Herein, we interrogated next‐generation sequencing (NGS)‐based genetic testing data of 10,759 NSCLC cases from a multicenter database with known *EGFR* mutations, which provided the opportunity to determine the prevalence of EGFR‐KDD alterations in a large sample set. We also evaluated the clinical significance of EGFR‐KDDs, aiming to provide valuable insights into the clinical efficacy of TKIs that target common *EGFR*‐sensitizing mutations against this alteration, and the potential drug‐resistance mechanisms arising during disease progression.

Methods {#ijc31895-sec-0002}
=======

We retrospectively reviewed records of 10,759 East Asian NSCLC patients who underwent genetic testing using capture‐based targeted NGS between August 2016 and April 2018 at hospitals across China, including the First Affiliated Hospital of Dalian Medical University (Liaoning, China), the First Affiliated Hospital of Zhengzhou University (Henan, China), the Beijing Tuberculosis and Thoracic Tumor Research Institute (Beijing, China), the First Affiliated Hospital of Nanjing Medical University (Jiangsu, China), the Affiliated Cancer Hospital & Institute of Guangzhou Medical University (Guangdong, China), and the Sun Yat‐sen University Cancer Centre (Guangdong, China). Written informed consent was collected from each patient upon sample collection according to the protocols approved by the ethical committee of each hospital. We identified patients with EGFR‐KDD alterations using a natural language search of the Laboratory Information Management System (LIMS) database for every *EGFR* mutation analysis performed on patients. Relevant demographic and clinical data were abstracted from the database for those cases, including age, gender, date of diagnosis, histology type, pathological stage, and evaluation of response after treatment with TKIs according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1).[8](#ijc31895-bib-0008){ref-type="ref"} Genomic profiling was performed by targeted sequencing of pan‐cancer relevant genes on post‐treatment samples from patients receiving TKI therapies.

Results {#ijc31895-sec-0003}
=======

A multi‐institutional database revealed a total of 10,759 patients diagnosed with NSCLCs between August 2016 and April 2018. Approximately 90.2% (9,704/10,759) of all patients were lung adenocarcinomas, and approximately 50.1% (5,394/10,759) of harbored *EGFR* mutations. EGFR‐KDD was identified in 13 patients (Table [1](#ijc31895-tbl-0001){ref-type="table"}), giving rise to the frequency of about 0.12% of the total NSCLCs and 0.24% of the *EGFR* mutation‐positive population. A total of 545 patients were identified with *EGFR* mutations other than *EGFR* L858R, ex19del, G719X, or L861Q, resulting in a frequency of 2.4% of EGFR‐KDD in the cohort bearing *EGFR* rare mutations.

###### 

Clinical information for NSCLC patients with EGFR‐KDD

  Patient ID   Age at diagnosis   Gender   Histology                      Stage   Type of EGFR‐KDD   Sample type (Pre‐/Post‐ TKI)   *EGFR* amplification status
  ------------ ------------------ -------- ------------------------------ ------- ------------------ ------------------------------ -----------------------------
  GS‐1         41                 Female   Lung adenocarcinoma            IV      exon 18--25        P, T/ NA                       no
  GS‐2         48                 Male     Lung adenocarcinoma            NA      exon 18--25        T/ NA                          *EGFR* amp (pre)
  GS‐3         61                 Male     Lung adenocarcinoma            IV      exon 18--25        P, T/ P                        *EGFR* amp (post)
  GS‐4         63                 Male     Lung adenocarcinoma            IV      exon 18--25        P/ NA                          no
  GS‐5         60                 Female   Lung adenocarcinoma            IV      exon 18--25        NA/ P                          *EGFR* amp (post)
  GS‐6         67                 Male     Lung adenocarcinoma            IV      exon 18--25        P, T/ NA                       no
  GS‐7         43                 Female   Lung adenocarcinoma            IV      exon 18--25        NA/ P                          *EGFR* amp (post)
  GS‐8         52                 Male     Lung adenocarcinoma            IV      exon 17--25        P, T/ NA                       no
  GS‐9         NA                 Male     Lung adenocarcinoma            NA      exon 18--25        T/ NA                          no
  GS‐10        55                 Female   Lung adenocarcinoma            IV      exon 18--25        P, T/ NA                       no
  GS‐11        87                 Male     Lung squamous cell carcinoma   IIA     exon 14--26        P, T/ NA                       no
  GS‐12        84                 Male     Lung adenocarcinoma            IV      exon 18--25        P/ NA                          no
  GS‐13        74                 Female   Lung adenocarcinoma            NA      exon 18--25        T/ NA                          no

NA, not available; P, plasma; T, tumor tissue.

The median age of EGFR‐KDD patients at primary diagnosis was 60 years (range: 41--87 years) (Table [1](#ijc31895-tbl-0001){ref-type="table"}). The male to female ratio of this cohort was 1.6:1. The stage of disease at diagnosis was 69.2% stage IV (9/13), 7.7% stage II (1/13), and the remaining three cases were undetermined. With the exception of one lung squamous cell carcinoma, all specimens were diagnosed with lung adenocarcinomas. Eight cases had an isolated EGFR‐KDD alteration, while three cases had a concurrent *EGFR* amplification. Eleven out of thirteen cases were identified with the previously described EGFR‐KDD that occurs in exons 18--25. However, the genomic breakpoints occurring in introns 17 and 25 varied between cases. Figure [1](#ijc31895-fig-0001){ref-type="fig"} *a* is representative of one example of such a case, while the other two patients were found to have atypical KDD events occurring in exons 17--25 and exons 14--26, respectively (Fig. [1](#ijc31895-fig-0001){ref-type="fig"} *b* and *c*). Furthermore, these EGFR‐KDD alterations were detected in plasma circulating cell‐free DNA (cfDNA) (Table [1](#ijc31895-tbl-0001){ref-type="table"}).

![Visualization of EGFR‐KDD variants using the IGV Browser. The bottom of each panel consists of the *EGFR* reference sequence with nucleotides shown. Blue vertical dashed lines indicate where the breakpoints were localized. *KDD* events include canonical exon 18--25 duplications in GS‐4 (*a*), and uncommon ones, such as exons 17--25 in GS‐8 (*b*) and exons 14--26 in GS‐11 (*c*).](IJC-144-2677-g001){#ijc31895-fig-0001}

Patients' treatment histories and their tumor responses to TKIs from our study and the literature are summarized in Table [2](#ijc31895-tbl-0002){ref-type="table"}. In our study, patients with EGFR‐KDD‐driven lung adenocarcinomas (*n* = 5) showed variable antitumor responses to *EGFR* TKIs. Two patients (GS‐3 and GS‐7) progressed shortly after undergoing therapies on *EGFR* TKIs, including gefitinib, erlotinib and osimertinib with a PFS of less than 3 months. The other two patients exhibited partial responses to TKI treatments. One patient\'s (GS‐4) tumor responded to osimertinib after a relapse on afatinib, while the other patient (GS‐5) remained stable on gefitinib therapy with a PFS of 11 months. A fifth case was observed with a partial antitumor response to the *VEGFR* inhibitor, apatinib, combined with the first‐generation *EGFR* TKI, Icotinib,[9](#ijc31895-bib-0009){ref-type="ref"} and is currently free of progressive disease. Targeted sequencing of post‐TKI samples revealed potential resistance mechanisms, including *EGFR* T790 M mutations (GS‐5), *EGFR* amplifications (GS‐3, GS‐5, and GS‐7), and missense mutations in *PIK3R1* (GS‐3) and *MAP2K4* (GS‐7); however, the clinical significance of such mutations remains unknown.

###### 

Summary of the responses of EGFR‐KDDs (exon 18--25) to targeted therapies in patients with the alteration

                                                                                                   Treatment and response                                                                                                                                                                                                                                                                                                      
  --------------------------------------------------------- -------------------------------------- ----------------------------------------------------------- ---------------------------------------------- -------------------------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------- -----------------------------
  our study                                                 GS‐3                                   Chemotherapy, targeted therapy (TKI, monoclonal antibody)   PD                                             (erlotinib, PD, 2 mo), (osimertinib, PD, 2 mo)                                         *EGFR*‐KDD, *TP53* R280G (plasma and tissue)                *EGFR*‐KDD, *EGFR* amp (1.6‐fold), *PIK3R1* Y463F (plasma)    *EGFR* amp, *PIK3R1* Y463F
                                                            GS‐4                                   Targeted therapy (TKI)                                      PR                                             (gefitinib, PR, 5 m0), (afatinib, PD, 2 mo), (osimertinib, PR, 4 mo \[Not reached\])   *EGFR*‐KDD, *ERBB2* amp (plasma)                            NA                                                            NA
                                                            GS‐5                                   Chemotherapy, targeted therapy (TKI)                        SD                                             (gefitinib, SD, 11 mo)                                                                 NA                                                          *EGFR*‐KDD, *EGFR* T790 M, *EGFR* amp (1.8‐fold) (plasma)     *EGFR* T790 M, *EGFR* amp
                                                            GS‐6                                   Chemotherapy, targeted therapy (TKI)                        PR                                             (apatinib + icotinib, PR, 4 mo \[Not reached\])                                        *EGFR*‐KDD, *TP53* Y220C, PIK3CA E81G (plasma and tissue)   NA                                                            NA
                                                            GS‐7                                   Chemotherapy, targeted therapy (TKI)                        PD                                             (gefitinib, PD, 3 mo), (erlotinib, PD, 5 mo)                                           NA                                                          *EGFR*‐KDD, *EGFR* amp (2.0‐fold), *MAP2K4* S12 fs (plasma)   *EGFR* amp, *MAP2K4* S12 fs
  Baik *et al* [5](#ijc31895-bib-0005){ref-type="ref"}      Targeted therapy (TKI)                 PR                                                          (gefitinib, PR, 6 yr), (erlotinib, PR, 3 yr)   not detected (tissue)                                                                  *EGFR* T790 M, *CTNNB1* S37C (tissue)                       *EGFR* T790 M, *CTNNB1* S37C                                  
  Gallant *et al* [6](#ijc31895-bib-0006){ref-type="ref"}   Chemotherapy, targeted therapy (TKI)   PR                                                          (afatinib, PR, 7 cycles, about 10 mo)          *EGFR* amp not detected (tissue)                                                       *EGFR* amp (tissue)                                         *EGFR* amp                                                    
  Wiest *et al* [11](#ijc31895-bib-0011){ref-type="ref"}    Chemotherapy, targeted therapy (TKI)   PR                                                          (afatinib, PR, NA)                             NA                                                                                     NA                                                          NA                                                            

PD, progressive disease; PR, partial response; SD, stable disease; NA, not available; AR, acquired resistance; amp, amplification.

Discussion {#ijc31895-sec-0004}
==========

In our study, we reported that EGFR‐KDDs comprised 0.12% of all NSCLCs and 0.24% of all *EGFR* aberrations, including the canonical KDD rearrangements involving exons 18--25 and uncommon rearrangements, such as duplications of exons 14--26 and exons 17--25 that have not previously been described. The frequencies of such rearrangements were slightly higher than the previously reported statistics of 0.07% of lung cancers (*N* = 7,200) reported by Gallant *et al*.[6](#ijc31895-bib-0006){ref-type="ref"} and 0.2% of the *EGFR*‐positive cohort (*N* = 1,510) reported by Costa *et al*.[10](#ijc31895-bib-0010){ref-type="ref"}. The higher frequency observed in our study is likely because *EGFR* mutations are more common in NSCLCs of ethnic Chinese individuals, compared to Caucasians.

EGFR‐KDD of exons 18--25 is the most frequent kinase domain duplication variant. Baik and colleagues reported the first case of this kind in a 45‐year‐old woman who was diagnosed with a nonmucinous bronchoalveolar carcinoma.[5](#ijc31895-bib-0005){ref-type="ref"} The patient demonstrated a partial response to the first‐generation EGFR TKIs, including gefitinib and erlotinib, while resistance subsequently developed with the emergence of *EGFR* T790 M and *CTNNB1* S37F missense mutations (Table [2](#ijc31895-tbl-0002){ref-type="table"}). Another case study also reported a EGFR‐KDD of exons 18--25 in a 33‐year‐old male, which showed a preferable antitumor response to the second generation *EGFR* TKI, afatinib.[6](#ijc31895-bib-0006){ref-type="ref"} Furthermore, the effect of afatinib in suppressing tumors harboring EGFR‐KDD of exons 18--25 was also observed in a 72‐year‐old patient reported by Wiest and colleagues.[11](#ijc31895-bib-0011){ref-type="ref"} Here, we observed variable antitumor responses in a total of five patients who received targeted therapies, including gefitinib, erlotinib, osimertinib, and a *VEGFR* inhibitor, apatinib, revealing the therapeutic complexities and challenges associated with the treatment of patients with EGFR‐KDD aberrations. The best response was observed in patient GS‐5 who experienced a controlled disease while on gefitinib with a PFS of 11 months. Such stability was similar to the PFS seen in patients diagnosed with *EGFR* ex19del or L858R mutations,[12](#ijc31895-bib-0012){ref-type="ref"}, [13](#ijc31895-bib-0013){ref-type="ref"} further indicating that EGFR‐KDDs, although rare, are targetable tumor driver mutations. Subsequently, however, the *EGFR* T790 M mutation and *EGFR* amplification were detected in this patient\'s plasma ctDNA sample, and may explain the acquired resistance.

Kinase domain duplications are not only observed in *EGFR* as common genomic mechanisms underlying molecular adaption to the highly selective pressures and resistance to antibiotics and cancer therapies. In fact, *BRAF‐KDDs* have also been reported in gliomas.[14](#ijc31895-bib-0014){ref-type="ref"} More recently, the analysis of 50,000 samples spanning multiple tumor types found that *BRAF‐KDDs* comprised 0.5% of all *BRAF* alterations identified.[15](#ijc31895-bib-0015){ref-type="ref"} Additionally, KDD events were identified in other genes, including *MET, FGFR1, FGFR3, RET, ERBB2, ALK*, and *NTRK* in different types of tumors as potential driver mutations.[16](#ijc31895-bib-0016){ref-type="ref"} It is therefore important to increase the panel coverage of intronic regions of such kinases for comprehensive NGS analyses in the future.

In summary, our study provided valuable insight into the prevalence and clinical outcomes of EGFR‐KDDs in NSCLCs. Our findings suggested that such rearrangements are clinically important genomic alterations and provide therapeutic targets for TKI treatments. Thus, the clinical incorporation of tumor‐profiling technologies is likely to further refine the clinicopathologic features of EGFR‐KDDs, and provide avenues for more effective therapeutic strategies.
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